Characteristics and prognosis of primary treatment-naïve oral cavity squamous cell carcinoma in Norway, a descriptive retrospective study


Autoři: Inger-Heidi Bjerkli aff001;  Olav Jetlund aff003;  Gunnhild Karevold aff003;  Ása Karlsdóttir aff004;  Ellen Jaatun aff005;  Lars Uhlin-Hansen aff002;  Oddveig G. Rikardsen aff001;  Elin Hadler-Olsen aff002;  Sonja E. Steigen aff002
Působiště autorů: Department of Otorhinolaryngology, University Hospital of North Norway, Tromsø, Norway aff001;  Department of Medical Biology, UiT The Arctic University of Norway, Tromsø, Norway aff002;  Department of Otorhinolaryngology, Head and Neck Surgery, Division of Head, Neck and Reconstructive Surgery, Oslo University Hospital—Rikshospitalet, Oslo, Norway aff003;  Department of Oncology, Haukeland University Hospital, Bergen, Norway aff004;  Department of Otorhinolaryngology, St. Olavs University Hospital, Trondheim, Norway aff005;  Norwegian University of Science and Technology, Trondheim, Norway aff006;  Department of Pathology, University Hospital of North Norway, Tromsø, Norway aff007;  Department of Clinical Dentistry, UiT The Arctic University of Norway, Tromsø, Norway aff008
Vyšlo v časopise: PLoS ONE 15(1)
Kategorie: Research Article
doi: 10.1371/journal.pone.0227738

Souhrn

Objectives

Incidence of oral cavity squamous cell carcinomas is rising worldwide, and population characterization is important to follow for future trends. The aim of this retrospective study was to present a large cohort of primary oral cavity squamous cell carcinoma from all four health regions of Norway, with descriptive clinicopathological characteristics and five-year survival outcomes.

Materials and methods

Patients diagnosed with primary treatment-naïve oral cavity squamous cell carcinomas at all four university hospitals in Norway between 2005–2009 were retrospectively included in this study. Clinicopathological data from the electronic health records were compared to survival data.

Results

A total of 535 patients with primary treatment-naïve oral cavity squamous cell carcinomas were identified. The median survival follow-up time was 48 months (range 0–125 months) after treatment. The median five-year overall survival was found to be 47%. Median five-year disease-specific survival was 52%, ranging from 80% for stage I to 33% for stage IV patients. For patients given treatment with curative intent, the overall survival was found to be 56% and disease-specific survival 62%. Median age at diagnosis was 67 years (range 24–101 years), 64 years for men and 72 years for women. The male: female ratio was 1.2. No gender difference was found in neither tumor status (p = 0.180) nor node status (p = 0.266), but both factors influenced significantly on survival (p<0.001 for both).

Conclusions

We present a large cohort of primary treatment-naïve oral cavity squamous cell carcinomas in Norway. Five-year disease-specific survival was 52%, and patients eligible for curative treatment had a five-year disease-specific survival up to 62%.

Klíčová slova:

Alcohol consumption – Cancer detection and diagnosis – Cancer risk factors – Cancer treatment – Norway – Squamous cell carcinomas – Surgical and invasive medical procedures – Tongue


Zdroje

1. Shield KD, Ferlay J, Jemal A, Sankaranarayanan R, Chaturvedi AK, Bray F, et al. The global incidence of lip, oral cavity, and pharyngeal cancers by subsite in 2012. CA: a cancer journal for clinicians. 2017;67(1):51–64. doi: 10.3322/caac.21384 28076666.

2. Network NCC. National Comprehensive Cancer Network. Head and Neck Cancers. Version 2.2018 [21 January 2019]. Available from: https://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.

3. Wittekind C, F.L; G, Hutter RVP, Klimpfinger M, Sobin LH. TNM Atlas 5th Edition. 5th Edition 2005 ed. Berlin Heidelberg Germany: Springer-Verlag; 2005. p. 5–38.

4. Brierley JDG, M.K; Wittekind Ch; O'Sullivan B; Mason M; Asamura H; Lee A; Van Eycken E; Denny L; Amin M.B; Gupta S. TNM Classification of malignant Tumours Eight Edition. Oxford, UK: Wiley Blackwell; 2017. p. 17–54.

5. Mroueh R, Haapaniemi A, Grenman R, Laranne J, Pukkila M, Almangush A, et al. Improved outcomes with oral tongue squamous cell carcinoma in Finland. Head & neck. 2017;39(7):1306–12. doi: 10.1002/hed.24744 28481417.

6. Pires FR, Ramos AB, Oliveira JB, Tavares AS, Luz PS, Santos TC. Oral squamous cell carcinoma: clinicopathological features from 346 cases from a single oral pathology service during an 8-year period. Journal of applied oral science: revista FOB. 2013;21(5):460–7. doi: 10.1590/1679-775720130317 24212993; PubMed Central PMCID: PMC3881836.

7. Li R, Koch WM, Fakhry C, Gourin CG. Distinct epidemiologic characteristics of oral tongue cancer patients. Otolaryngology—head and neck surgery: official journal of American Academy of Otolaryngology-Head and Neck Surgery. 2013;148(5):792–6. doi: 10.1177/0194599813477992 23396594.

8. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2018;68(6):394–424. Epub 2018/09/13. doi: 10.3322/caac.21492 30207593.

9. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral oncology. 2009;45(4–5):309–16. doi: 10.1016/j.oraloncology.2008.06.002 18804401.

10. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. International journal of cancer Journal international du cancer. 2015;136(5):E359–86. doi: 10.1002/ijc.29210 25220842.

11. Gatta G, Botta L, Sanchez MJ, Anderson LA, Pierannunzio D, Licitra L, et al. Prognoses and improvement for head and neck cancers diagnosed in Europe in early 2000s: The EUROCARE-5 population-based study. European journal of cancer (Oxford, England: 1990). 2015;51(15):2130–43. doi: 10.1016/j.ejca.2015.07.043 26421817.

12. Annertz K, Anderson H, Palmer K, Wennerberg J. The increase in incidence of cancer of the tongue in the Nordic countries continues into the twenty-first century. Acta oto-laryngologica. 2012;132(5):552–7. doi: 10.3109/00016489.2011.649146 22339663.

13. Karnov KKS, Gronhoj C, Jensen DH, Wessel I, Charabi BW, Specht L, et al. Increasing incidence and survival in oral cancer: a nationwide Danish study from 1980 to 2014. Acta oncologica (Stockholm, Sweden). 2017;56(9):1204–9. doi: 10.1080/0284186X.2017.1307516 28366106.

14. Tota JE, Anderson WF, Coffey C, Califano J, Cozen W, Ferris RL, et al. Rising incidence of oral tongue cancer among white men and women in the United States, 1973–2012. Oral oncology. 2017;67:146–52. doi: 10.1016/j.oraloncology.2017.02.019 28351569.

15. Barnes LE, J.W; Reichart P; Sidransky D. Pathology and Genetics of Head and Neck Tumours. Pathology & Genetics of Head and Neck Tumours. Lyon France: IARC Press; 2005. p. 163–75.

16. Rikardsen OG, Bjerkli IH, Uhlin-Hansen L, Hadler-Olsen E, Steigen SE. Clinicopathological characteristics of oral squamous cell carcinoma in Northern Norway: a retrospective study. BMC oral health. 2014;14(1):103. doi: 10.1186/1472-6831-14-103 25135120.

17. de Abreu PM, Co ACG, Azevedo PL, do Valle IB, de Oliveira KG, Gouvea SA, et al. Frequency of HPV in oral cavity squamous cell carcinoma. BMC cancer. 2018;18(1):324. doi: 10.1186/s12885-018-4247-3 29580212; PubMed Central PMCID: PMC5870524.

18. Weatherspoon DJ, Chattopadhyay A, Boroumand S, Garcia I. Oral cavity and oropharyngeal cancer incidence trends and disparities in the United States: 2000–2010. Cancer epidemiology. 2015;39(4):497–504. doi: 10.1016/j.canep.2015.04.007 25976107; PubMed Central PMCID: PMC4532587.

19. Maasland DH, van den Brandt PA, Kremer B, Goldbohm RA, Schouten LJ. Alcohol consumption, cigarette smoking and the risk of subtypes of head-neck cancer: results from the Netherlands Cohort Study. BMC cancer. 2014;14:187. doi: 10.1186/1471-2407-14-187 24629046; PubMed Central PMCID: PMC4004328.

20. Conway DI, Purkayastha M, Chestnutt IG. The changing epidemiology of oral cancer: definitions, trends, and risk factors. Br Dent J. 2018;225(9):867–73. doi: 10.1038/sj.bdj.2018.922 30412558.

21. Rosenquist K, Wennerberg J, Schildt EB, Bladstrom A, Goran Hansson B, Andersson G. Oral status, oral infections and some lifestyle factors as risk factors for oral and oropharyngeal squamous cell carcinoma. A population-based case-control study in southern Sweden. Acta oto-laryngologica. 2005;125(12):1327–36. doi: 10.1080/00016480510012273 16303683.

22. Chang JS, Lo H-I, Wong T-Y, Huang C-C, Lee W-T, Tsai S-T, et al. Investigating the association between oral hygiene and head and neck cancer. Oral oncology. 2013;49(10):1010–7. doi: 10.1016/j.oraloncology.2013.07.004 23948049

23. Javed F, Warnakulasuriya S. Is there a relationship between periodontal disease and oral cancer? A systematic review of currently available evidence. Critical reviews in oncology/hematology. 2016;97:197–205. doi: 10.1016/j.critrevonc.2015.08.018 26343577.

24. Rennemo E, Zatterstrom U, Evensen J, Boysen M. Reduced risk of head and neck second primary tumors after radiotherapy. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2009;93(3):559–62. doi: 10.1016/j.radonc.2009.08.005 19747745.

25. Braakhuis BJ, Tabor MP, Leemans CR, van der Waal I, Snow GB, Brakenhoff RH. Second primary tumors and field cancerization in oral and oropharyngeal cancer: molecular techniques provide new insights and definitions. Head & neck. 2002;24(2):198–206. Epub 2002/03/14. doi: 10.1002/hed.10042 11891950.

26. Schwartz LH, Ozsahin M, Zhang GN, Touboul E, De Vataire F, Andolenko P, et al. Synchronous and metachronous head and neck carcinomas. Cancer. 1994;74(7):1933–8. doi: 10.1002/1097-0142(19941001)74:7<1933::aid-cncr2820740718>3.0.co;2-x 8082099.

27. Digonnet A, Hamoir M, Andry G, Haigentz M Jr., Takes RP, Silver CE, et al. Post-therapeutic surveillance strategies in head and neck squamous cell carcinoma. European archives of oto-rhino-laryngology: official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS): affiliated with the German Society for Oto-Rhino-Laryngology—Head and Neck Surgery. 2013;270(5):1569–80. Epub 2012/09/14. doi: 10.1007/s00405-012-2172-7 22972497.

28. Montero PH, Patel SG. Cancer of the oral cavity. Surgical oncology clinics of North America. 2015;24(3):491–508. Epub 2015/05/17. doi: 10.1016/j.soc.2015.03.006 25979396; PubMed Central PMCID: PMC5018209.

29. Miller MC, Goldenberg D, Education Committee of the American H, Neck S. AHNS Series: Do you know your guidelines? Principles of surgery for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. Head & neck. 2017;39(4):791–6. doi: 10.1002/hed.24654 27987243.

30. Gooi Z, Fakhry C, Goldenberg D, Richmon J, Kiess AP, Education Committee of the American H, et al. AHNS Series: Do you know your guidelines?Principles of radiation therapy for head and neck cancer: A review of the National Comprehensive Cancer Network guidelines. Head & neck. 2016;38(7):987–92. doi: 10.1002/hed.24448 27015108.

31. Cheng YJ, Tsai MH, Chiang CJ, Tsai ST, Liu TW, Lou PJ, et al. Adjuvant radiotherapy after curative surgery for oral cavity squamous cell carcinoma and treatment effect of timing and duration on outcome-A Taiwan Cancer Registry national database analysis. Cancer Med. 2018. Epub 2018/06/16. doi: 10.1002/cam4.1611 29905028; PubMed Central PMCID: PMC6051157.

32. Torrecillas V, Shepherd HM, Francis S, Buchmann LO, Monroe MM, Lloyd S, et al. Adjuvant radiation for T1-2N1 oral cavity cancer survival outcomes and utilization treatment trends: Analysis of the SEER database. Oral oncology. 2018;85:1–7. Epub 2018/09/18. doi: 10.1016/j.oraloncology.2018.07.019 30220313.

33. Chang S, Sanii R, Chaudhary H, Lewis C, Seidman M, Yaremchuk K. Evaluation of early oral cavity cancer treatment quality at a single institution. The Laryngoscope. 2019;129(8):1816–21. Epub 2018/11/09. doi: 10.1002/lary.27565 30408196.

34. Group tDHaNC. Retningslinjer for stålebehandling i DAHANCA 2018 [17.06.2019]. Available from: https://www.dahanca.dk/assets/files/GUID_DAHANCA%20straaleretningslinjer.pdf.

35. Ruhstaller T, Roe H, Thurlimann B, Nicoll JJ. The multidisciplinary meeting: An indispensable aid to communication between different specialities. European journal of cancer (Oxford, England: 1990). 2006;42(15):2459–62. doi: 10.1016/j.ejca.2006.03.034 16934974.

36. Mehanna H, West CM, Nutting C, Paleri V. Head and neck cancer—Part 2: Treatment and prognostic factors. Bmj. 2010;341:c4690. doi: 10.1136/bmj.c4690 20876637.

37. Society AC. Survival Rates for Oral Cavity and Oropharyngeal Cancer: American Cancer Society; 2019 [updated February 6, 2019]. Available from: https://www.cancer.org/cancer/oral-cavity-and-oropharyngeal-cancer/detection-diagnosis-staging/survival-rates.html. doi: 10.1002/cncr.32208

38. ICD-10 W. International Statistical Classification of Diseases and Related Health Problems 10th Revision 2016 [cited 2016 June 19 2019]. Available from: https://icd.who.int/browse10/2016/en.

39. Norway S. Alcohol Consumption in Norway [cited 2019 23 January 2019]. Available from: https://www.ssb.no/en/statbank/table/12392.

40. Wirsing AM, Rikardsen OG, Steigen SE, Uhlin-Hansen L, Hadler-Olsen E. Characterisation and prognostic value of tertiary lymphoid structures in oral squamous cell carcinoma. BMC clinical pathology. 2014;14:38. doi: 10.1186/1472-6890-14-38 25177210.

41. Gussgard AM, Hope AJ, Jokstad A, Tenenbaum H, Wood R. Assessment of cancer therapy-induced oral mucositis using a patient-reported oral mucositis experience questionnaire. PloS one. 2014;9(3):e91733. doi: 10.1371/journal.pone.0091733 24614512; PubMed Central PMCID: PMC3948915.

42. Karamzad N, Ayubi E, Rahmani V, Safiri S. Hypertension is the primary component of metabolic syndrome associated with pathologic features of kidney cancer: methodological issues. World journal of urology. 2017;35(9):1467–8. Epub 2016/11/20. doi: 10.1007/s00345-016-1974-4 27864618.

43. Safiri S, Ayubi E. Dual photon microscopy based quantitation of fibrosis-related parameters (q-FP) to model disease progression in steatohepatitis: Methodological issues. Hepatology. 2017;66(3):998–9. doi: 10.1002/hep.29261 28510294.

44. Ayubi E, Safiri S. Lateral lymph node recurrence after total thyroidectomy and central neck dissection in patients with papillary thyroid cancer without clinical evidence of lateral neck metastasis: Comment on data sparsity. Oral oncology. 2017;69:128. Epub 2017/04/22. doi: 10.1016/j.oraloncology.2017.04.006 28427760.

45. Mariotto AB, Noone AM, Howlader N, Cho H, Keel GE, Garshell J, et al. Cancer survival: an overview of measures, uses, and interpretation. J Natl Cancer Inst Monogr. 2014;2014(49):145–86. Epub 2014/11/25. doi: 10.1093/jncimonographs/lgu024 25417231; PubMed Central PMCID: PMC4829054.

46. Eurostat. Eurostat Statistics, Tobacco Consumption 2014 [5 February 2019]. Available from: https://ec.europa.eu/eurostat/statistics-explained/index.php?title=Tobacco_consumption_statistics.

47. WHO. Global status report on alcohol and healt 2018 Geneva: World Health Organization; 2018 [1 February 2019]. CC BY-NC-SA 3.0 IGO [Report]. Available from: https://www.who.int/substance_abuse/publications/global_alcohol_report/en/.

48. WHO E. Alcohol Consumption European Countries [5 february 2019]. Available from: http://www.euro.who.int/en/health-topics/disease-prevention/alcohol-use/publications/2018/alcohol-consumption,-harm-and-policy-response-fact-sheets-for-30-european-countries-2018.

49. Fakhry C, Psyrri A, Chaturvedhi A. HPV and head and neck cancers: state-of-the-science. Oral oncology. 2014;50(5):353–5. doi: 10.1016/j.oraloncology.2014.03.010 24726207.

50. Benson E, Li R, Eisele D, Fakhry C. The clinical impact of HPV tumor status upon head and neck squamous cell carcinomas. Oral oncology. 2014;50(6):565–74. doi: 10.1016/j.oraloncology.2013.09.008 24134947; PubMed Central PMCID: PMC4391706.

51. Taberna M, Mena M, Pavon MA, Alemany L, Gillison ML, Mesia R. Human papillomavirus-related oropharyngeal cancer. Annals of oncology: official journal of the European Society for Medical Oncology / ESMO. 2017;28(10):2386–98. doi: 10.1093/annonc/mdx304 28633362.

52. Norway S. Tobacco, alcohol and other drugs 2019 [12 February 2019]. Available from: https://www.ssb.no/en/helse/statistikker/royk.


Článek vyšel v časopise

PLOS One


2020 Číslo 1